Simplex Trading
NTLA icon

Simplex Trading’s Intellia Therapeutics NTLA Stock Holding History

Simplex Trading’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.23M Sell
407,900
-43,700
-10% -$557K ﹤0.01% 1090
2025
Q4 		$4.06M Buy
451,600
+185,800
+70% +$2.56M ﹤0.01% 1445
2025
Q3 		$4.59M Buy
265,800
+137,200
+107% +$1.69M ﹤0.01% 1539
2025
Q2 		$1.21M Buy
128,600
+32,100
+33% +$264K ﹤0.01% 2593
2025
Q1 		$686K Sell
96,500
-205,800
-68% -$2.08M ﹤0.01% 3057
2024
Q4 		$3.52M Buy
302,300
+268,400
+792% +$4.19M ﹤0.01% 1727
2024
Q3 		$696K Sell
33,900
-37,200
-52% -$858K ﹤0.01% 3259
2024
Q2 		$1.59M Buy
71,100
+33,100
+87% +$788K ﹤0.01% 2426
2024
Q1 		$1.04M Buy
38,000
+11,800
+45% +$328K ﹤0.01% 3070
2023
Q4 		$798K Buy
26,200
+9,500
+57% +$273K ﹤0.01% 3238
2023
Q3 		$528K Sell
16,700
-4,100
-20% -$159K ﹤0.01% 3341
2023
Q2 		$848K Buy
20,800
+4,100
+25% +$166K ﹤0.01% 2758
2023
Q1 		$622K Buy
16,700
+6,900
+70% +$271K ﹤0.01% 3047
2022
Q4 		$341K Buy
9,800
+3,600
+58% +$171K ﹤0.01% 3587
2022
Q3 		$346K Sell
6,200
-3,000
-33% -$186K ﹤0.01% 3904
2022
Q2 		$476K Sell
9,200
-3,200
-26% -$162K ﹤0.01% 3497
2022
Q1 		$901K Buy
12,400
+8,900
+254% +$754K ﹤0.01% 3040
2021
Q4 		$413K Sell
3,500
-55,900
-94% -$7M ﹤0.01% 4077
2021
Q3 		$10.2M Sell
59,400
-200
-0.3% -$30.3K 0.01% 714
2021
Q2 		$9.65M Buy
59,600
+59,381
+27,115% +$4.62M 0.01% 733
2021
Q1 		$1.76M Buy
219
+25
+13% +$1.68K ﹤0.01% 1754
2020
Q4 		$1.05M Sell
194
-108
-36% -$3.92K ﹤0.01% 2482
2020
Q3 		$600K Buy
302
+232
+331% +$4.84K ﹤0.01% 2787
2020
Q2 		$147K Buy
70
+49
+233% +$832 ﹤0.01% 4359
2020
Q1 		$25K Sell
21
-417
-95% -$5.62K ﹤0.01% 5767
2019
Q4 		$642K Buy
438
+110
+34% +$1.53K ﹤0.01% 2503
2019
Q3 		$437K Sell
328
-19
-5% -$303 ﹤0.01% 2758
2019
Q2 		$568K Buy
347
+155
+81% +$2.44K ﹤0.01% 2450
2019
Q1 		$327K Buy
192
+146
+317% +$2.18K ﹤0.01% 3106
2018
Q4 		$62K Buy
46
+2
+5% +$37 ﹤0.01% 4325
2018
Q3 		$125K Buy
44
+12
+38% +$349 ﹤0.01% 4191
2018
Q2 		$87K Sell
32
-380
-92% -$9.21K ﹤0.01% 4448
2018
Q1 		$20K Buy
412
+138
+50% +$3.39K ﹤0.01% 3359
2017
Q4 		$38K Buy
274
+135
+97% +$3.12K ﹤0.01% 2696
2017
Q3 		$75K Sell
139
-191
-58% -$3.6K ﹤0.01% 1956
2017
Q2 		$39K Buy
+330
New +$4.61K ﹤0.01% 2622

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading's NTLA Position: Q4 2025 in Review

Simplex Trading sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 147,300 shares — an estimated $2.03M sold.

Simplex Trading first reported a position in NTLA in Q1 2017 and held it in 27 quarters. The position peaked at $2.54M in Q3 2025. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Simplex Trading reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 147,300 Intellia Therapeutics shares in Q4 2025, an estimated $2.03M.
  • Simplex Trading first reported a position in Intellia Therapeutics in Q1 2017 and held it in 27 quarters.
  • Simplex Trading's Intellia Therapeutics position peaked at $2.54M in Q3 2025.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.